![]() The majority of MDS diagnoses are “lower-risk” diseases (LR-MDS), indicating a relatively lower risk of death or progression to AML in the immediate period after diagnosis. MDS occurs in all age groups but mainly affects the elderly, with a median age of onset above 70 years. Myelodysplastic syndromes (MDS) comprise a heterogeneous group of hematopoietic stem and progenitor cell disorders characterized by ineffective hematopoiesis leading to dysplasia, cytopenias, and an increased risk of evolution to acute myeloid leukemia (AML). We discuss how next-generation sequencing, increasing knowledge on mechanisms of MDS pathogenesis, and novel therapies may change the current treatment landscape in LR-MDS and why structured assessments of responses, toxicities, and patient-reported outcomes should be incorporated into routine clinical practice. In this review, we focus on the diagnosis, prognosis, and treatment options, as well as the prediction of the disease course and monitoring of treatment response in patients with LR-MDS. As treatment goals for patients with LR-MDS and those with HR-MDS differ significantly, appropriate diagnosis, classification, and follow-up are critical for correct disease management. Patients with MDS can generally be classified as lower- (LR-MDS) or higher-risk (HR-MDS). Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic stem cell disorders characterized by ineffective hematopoiesis with abnormal blood cell development (dysplasia) leading to cytopenias and an increased risk for progression to acute myeloid leukemia (AML). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |